代谢相关性脂肪性肝病患者吸入性有机化合物与炎症指标的关系:基于2017～2020年美国国家健康与营养调查数据库资料分析*

doi:10.3969/j.issn.1672-5069.2025.03.008

摘要/Abstract

摘要： 目的探讨代谢相关性脂肪性肝病(MAFLD)患者全身炎症反应指数(SIRI)和全身免疫炎症指数(SII)与吸入性有机化合物(VOCs)之间的关系。方法检索2017年～2020年美国国家健康与营养调查数据库(NHANES),获得数据库中实验室检查结果和综合问卷调查结果,筛选出符合MAFLD诊断的患者,收集其血清VOCs水平和移动中心检查的血液指标数据,计算SIRI和SII。采用多变量回归模型分析两种炎症指标与血清VOCs水平的关系。结果 2991例MAFLD患者SII为(531±325),SIRI为(1.8±1.01),血清1,4-二氯苯水平为(1.2±8.2)ng/mL,血清2,5-二甲基呋喃水平为(0.1±0.1)ng/mL;MAFLD患者血清2,5-二甲基呋喃与SIRI(r=0.3,P<0.05)和SII(r=0.3, P<0.05)均成正相关;经多变量回归模型分析发现血清2,5-二甲基呋喃在不调整的模型中均与SIRI(β=1.8±0.3,P<0.05)和SII(β=696.8±122.4,P<0.05)呈正相关;模型经过年龄调整后,它们仍呈正相关(SIRI:β=2.0±0.3,P<0,05; SII:β=709.1±123.9,P<0,05);经过对年龄、性别、体质指数(BMI)、腰围(WC)、吸烟、高血压、糖尿病、总甘油三酯(TG)、谷丙转氨酶(ALT)、高密度脂蛋白(HDL)和超敏C反应蛋白(hsCRP)进行调整后发现血清2,5-二甲基呋喃水平仍与SIRI(β=1.7±0.3,P<0.05)和SII(β=655.8±122.4,P<0.05)呈正相关。结论 MAFLD患者暴露在更多的2,5-二甲基呋喃环境中可能能加重全身炎症反应程度,或成为引起疾病的因素之一。

Abstract: Objective The aim of this study was to investigate correlation of serum volatile organic compounds (VOCs) to and body inflammatory index in patients with metabolism-related fatty liver disease(MAFLD): an analysis based on 2017-2020 National Health and Nutrition Examination Survey database (NHANES). Methods Data from NHANES database from 2017 to 2020 were retrieved, patients who met diagnosis of MAFLD were enrolled and their laboratory tests, including serum VOCs levels and results of questionnaires were collected. Systemic inflammatory response index (SIRI) and systemic iImmunoinflammatory index (SII) were calculated. Multivariate Logistic regression modeling was applied to analyze correlation of the two inflammatory indicators to serum VOC content. Results SII in 2991 patients with MAFLD was (531±325), SIRI was (1.8±1.01), serum 1,4-dichlorobenzene level was (1.2±8.2) ng/mL, and serum 2,5-dimethylfuran level was (0.1±0.1) ng/mL; serum 2,5-dimethylfuran level was positively correlated with SIRI (r=0.3, P<0.05) and with SII (r=0.3, P<0.05) in patients with MAFLD; by multivariate Logistic regression modeling analysis, serum 2,5-dimethylfuran level was found to be associated with SIRI (β=1.8±0.3, P<0.05) and with SII (β=696.7±122.4, P<0.05) in unadjusted model; the model adjusted by age found that SIRI (β=2.0±0.3, P<0.05) and SII (β=709.1±123.9, P<0.05) were positively correlated to serum 2,5-dimethylfuran level; serum 2,5-dimethylfuran level was found to be still correlated to SIRI (β=1.7±0.3, P<0.05) or to SII (β=655.8±129.7, P<0.05) by adjusting the model for age, gender, body mass index (BMI), waist circumference (WC), smoking, hypertension, diabetes, total triglycerides (TG), alanine Aminotransferase (ALT), high-density lipoprotein (HDL) and high sensitivity C-reactive protein (hsCRP). Conclusion Exposure of individuals to higher levels of 2,5-dimethylfuran could exacerbate body systemic inflammatory response, which might trigger MAFLD occurrence.

Key words: Metabolism-related fatty liver disease, Volatile organic compounds, Systemic inflammatory response index, Systemic immunoinflammatory index, Multivariate Logistic regression analysis

代子行, 袁慧, 陈庆灵, 朱传龙, 李毓雯. 代谢相关性脂肪性肝病患者吸入性有机化合物与炎症指标的关系:基于2017～2020年美国国家健康与营养调查数据库资料分析^*[J]. 实用肝脏病杂志, 2025, 28(3): 350-353.

Dai Zixing, Yuan Hui, Chen Qingling, et al. Correlation of serum volatile organic compounds to body inflammatory index in patients with metabolism-related fatty liver disease: an analysis based on 2017-2020 National Health and Nutrition Examination Survey database[J]. Journal of Practical Hepatology, 2025, 28(3): 350-353.

参考文献

[1] Gofton C, Upendran Y, Zheng MH, et al. MAFLD: How is it different from NAFLD? Clin Mol Hepatol,2023,29(S1): S17-S31.
[2] Muthiah M, Ng CH, Chan KE, et al. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis. Ann Hepatol,2023,28(1): e100762.
[3] Guerreiro GTS, Longo L, Fonseca MA, et al. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int,2021,15(2): 380-391.
[4] Ayada I, van Kleef LA, Alferink LJM, et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. Liver Int,2022,42(2): 277-287.
[5] Torre P, Motta BM, Sciorio R, et al. Inflammation and fibrogenesis in MAFLD: Role of the hepatic immune system. Front Med (Lausanne),2021,8: e781567.
[6] Dong W, Gong Y, Zhao J, et al. A combined analysis of TyG index, SII index, and SIRI index: positive association with CHD risk and coronary atherosclerosis severity in patients with NAFLD. Front Endocrinol (Lausanne),2023,14: e1281839.
[7] Wang W, Guo XL, Qiu XP, et al. Systemic immune-inflammation index mediates the association between metabolic dysfunction-associated fatty liver disease and sub-clinical carotid atherosclerosis: a mediation analysis. Front Endocrinol (Lausanne),2024,15: e1406793.
[8] David E, Niculescu V-C. Volatile organic compounds (VOCs) as environmental pollutants: Occurrence and mitigation using nanomaterials. Int J Environ Res Public Health,2021,18(24): e132453.
[9] Kwon JW, Park HW, Kim WJ, et al. Exposure to volatile organic compounds and airway inflammation. Environ Health,2018,17(1): 65-66.
[10] Paulose-Ram R, Graber JE, Woodwell D, et al. The National Health and Nutrition Examination Survey (NHANES), 2021-2022: Adapting data collection in a COVID-19 environment. Am J Public Health,2021,111(12): 2149-2156.
[11] Luo S, Liu Z, Jiao R, et al. The associations of two novel inflammation indexes, systemic immune-inflammation index (SII) and system inflammation response index (SIRI), with periodontitis: evidence from NHANES 2009-2014. Clin Oral Investig,2024,28(2): 129-130.
[12] Mosslemi M, Park HL, McLaren CE, et al. A treatment-based algorithm for identification of diabetes type in the National Health and Nutrition Examination Survey. Cardiovasc Endocrinol Metab,2020,9(1): 189-199.
[13] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol,2020,73(1): 202-209.
[14] Liu Q, Han M, Li M, et al. Shift in prevalence and systemic inflammation levels from NAFLD to MAFLD: a population-based cross-sectional study. Lipids Health Dis,2023,22(1): 185-188.
[15] Wang X, Chen Z, Cheng D, et al. Association between urinary metabolites of volatile organic compounds and cardiovascular disease in the general population from NHANES 2011-2018. Ecotoxicol Environ Saf,2023,264(3): e115412.
[16] Wang X, He W, Wu X, et al. Exposure to volatile organic compounds is a risk factor for diabetes: A cross-sectional study. Chemosphere,2023,338(5):139424.
[17] McGraw KE, Riggs DW, Rai S, et al. Exposure to volatile organic compounds - acrolein, 1,3-butadiene, and crotonaldehyde - is associated with vascular dysfunction. Environ Res,2021,196(1): e110903.
[18] Liu W, Cao S, Shi D, et al. Single-chemical and mixture effects of multiple volatile organic compounds exposure on liver injury and risk of non-alcoholic fatty liver disease in a representative general adult population. Chemosphere,2023,339(1): e139753.
[19] Choi YH, Lee JY, Moon KW. Exposure to volatile organic compounds and polycyclic aromatic hydrocarbons is associated with the risk of non-alcoholic fatty liver disease in Korean adolescents: Korea National Environmental Health Survey (KoNEHS) 2015-2017. Ecotoxicol Environ Saf,2023,251: e114508.
[20] Chaiklieng S, Suggaravetsiri P, Autrup H. Risk assessment on benzene exposure among gasoline station workers. Int J Environ Res Public Health,2019,16(14): e142.
[21] Cho SI, Damokosh AI, Ryan LM, et al. Effects of exposure to organic solvents on menstrual cycle length. J Occup Environ Med,2001,43(6): 567-575.

代谢相关性脂肪性肝病患者吸入性有机化合物与炎症指标的关系:基于2017～2020年美国国家健康与营养调查数据库资料分析^*

Correlation of serum volatile organic compounds to body inflammatory index in patients with metabolism-related fatty liver disease: an analysis based on 2017-2020 National Health and Nutrition Examination Survey database

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价

[1]	苏雅, 王炳元. 酒精性肝病不是代谢相关性脂肪性肝病[J]. 实用肝脏病杂志, 2025, 28(1): 5-8.
[2]	柳雅立, 张晶. 儿童和青少年代谢相关脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2024, 27(4): 488-491.
[3]	董旭, 秦阳华, 陈怡, 许明晓, 葛玲玲, 徐圣, 廖威. 预后营养指数联合全身免疫炎症指数评估乙型肝炎相关慢加急性肝衰竭患者预后临床价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 390-393.
[4]	杨蕊旭, 齐明华. 慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*[J]. 实用肝脏病杂志, 2023, 26(6): 773-776.
[5]	施漪雯, 范建高. 代谢相关性脂肪性肝病流行现状[J]. 实用肝脏病杂志, 2023, 26(6): 777-780.
[6]	张淮, 郑明华. MAFLD高危人群的筛查和分层管理^*[J]. 实用肝脏病杂志, 2023, 26(4): 463-465.
[7]	米朦, 卢秉久, 王学良, 王晓彤, 郑佳连. 代谢相关性脂肪性肝病患者血脂分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 653-656.
[8]	朱南南, 蒋晓红, 周佳雁, 黄小琳, 刘雅旻. 2型糖尿病合并代谢相关性脂肪性肝病患者血尿酸水平变化和其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(6): 839-842.
[9]	首第文, 周永健, 徐豪明, 唐文娟, 骆庆玲, 梅情, 宁钢, 赵冲, 黄红丽, 曹创裕, 陈慧婷. 代谢相关性脂肪性肝病小鼠不同高脂饮食时期血糖水平和肠道菌群变化动态分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 661-664.
[10]	徐春玲, 苗重昌, 刘雨成, 张雪, 史曙光, 李树芸. 应用MRI多回波水脂分离技术评估代谢相关性脂肪性肝病患者肝脏脂肪含量的临床意义[J]. 实用肝脏病杂志, 2021, 24(2): 220-223.